Description: NADSAR is a non-peptide angiotensin II receptor (type AT1) antagonist. NADSAR is available as tablets for oral administration, containing 20mg or 40mg of Telmisartan.
Indication:
Treatment of essential hypertension in adults. Cardiovascular prevention: Reduction of cardiovascular morbidity in adults with: -manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or -Type 2 diabetes mellitus with documented target organ damage.